MARIE THOMPSON: Open Payments
NPI 1609298280 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,303 in 63 payments from 13 companies in 2025. Trend: 2023 $1,523 · 2024 $1,866 · 2025 $1,303
Food & beverage: $1,303
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $296 |
| Neurocrine BioSciences, Inc. | 12 | $224 |
| ABBVIE INC. | 8 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $153 |
| E.R. Squibb & Sons, L.L.C. | 6 | $116 |
| Lundbeck LLC | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Alkermes, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
Products named: REXULTI, INGREZZA, VRAYLAR, CAPLYTA, COBENFY, TRINTELLIX, ARISTADA, Auvelity.
Industry payments across NY — which companies pay providers there.
